Myelofibrosis is a rather dangerous disease. It manifests itself in the fact that the bone marrow is not able to produce the required number of blood cells, and gradually begins to be replaced by scar tissue. From this pathology, the spleen grows, severe pains in the bones and abdominal cavity begin, severe sweating occurs, which most of all worries at night, body weight is drastically lost. Jakavi (Ruxolitinib) 20mg - Jakavi (Ruxolitinib)- a drug developed by Swiss scientists is able to stop the development of myelofibrosis in adults, thanks to the drug, the size of the spleen begins to decrease, and the symptoms of the disease are not so disturbed. Composition of the preparation: • ruxolitinib is an active ingredient; • lactose monohydrite - is auxiliary. Jakavi is a drug that has a beneficial effect on the patient, but you must not use it without consulting your doctor. Before starting a course of therapy with Jakavi, it is imperative to conduct a laboratory blood test. Only after the results can it be determined what the initial dose of the drug is needed. But during treatment, constant blood tests will also be necessary so that the attending physician can control the level of leukocytes, erythrocytes and platelets. The obtained indicators will help to give a real picture of the therapeutic process and show how the treatment helps. Often, blood data make it necessary to select a different dose for the treatment to be more effective. You can read about the drugJakavi (Ruxolitinib) 20mg - Jakavi (Ruxolitinib) reviews on forums - as a rule, they are positive.
Side effects It happens that while taking the drug, phenomena occur due to which the patient is forced to refuse such treatment. First of all, this is an allergic reaction that occurs in relation to the main component - ruxolitinib, or another ingredient, for example, lactose. The drug can cause such phenomena as: • frequent infections, especially herpes zoster; • hemorrhage and bleeding; • constant weakness, shortness of breath and fatigue; • pallor of the skin; • persistent cough with phlegm in which blood clots can be found; • impaired coordination, confusion. The doctor must be notified of these changes immediately. He should also know if other medicines are taken in parallel or if there are other diseases. Maybe then you need to change the dose of Jakavi. This drug is not recommended for pregnant women. as well as during lactation. If you are interested inJakavi (Ruxolitinib) 20mg - Jakavi (Ruxolitinib) cost - the current price can be checked with the employee of our online pharmacy.
©2020 CopyRight Onco24.com. All rights reserved.